RxDoctor Payments Data

Lakshmi Duvvur, MD

Nephrology · Topeka, KSNPI 1790877660

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Bayer at 51.7% of the total. Reporting peaked in 2021 at $168 and has fallen 84.8% since, to $26 in 2025. That places this record below the midpoint for nephrology clinicians in KS, where the typical reported total is $931.

$326in general payments, 2019–2025

Across 10 payments — averaging $32.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$168
  • AstraZeneca$37
  • Akebia Therapeutics Inc$31
  • Vantive US Healthcare LLC$26
  • Daiichi Sankyo Inc.$21
  • Amgen$20
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$30694%
  • Education$206%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$326 in reported general payments places this provider in the 30th percentile of 55 nephrology providers in Kansas.

See all nephrology providers in Kansas

Medicare billing

Part B allowed, 2024
$305,783
Medicare patients
859
Services billed
4,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide20$77,116
VeltassaPatiromer Calcium Sorbitex12$22,840
FarxigaDapagliflozin Propanediol26$21,449
Sevelamer Carbonate40$11,808
Calcium Acetate54$4,104
Potassium Citrate ErPotassium Citrate17$2,112
Midodrine Hcl26$1,203
Potassium Chloride59$975
Amlodipine Besylate153$852
Losartan Potassium100$748
Torsemide38$591
Carvedilol102$588
Furosemide130$561
Terazosin Hcl21$365
Allopurinol44$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$37$21,44926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 55 nephrology providers in Kansas.

Other nephrology in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →